BEIJING, China--(BUSINESS WIRE)--Avistone Biotechnology Co., Ltd (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Tyrosine kinase inhibitors (TKIs) are emerging as a ...

Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A ...

In this discussion, panelists explore the potential role of new Bruton tyrosine kinase inhibitors in the treatment landscape for chronic spontaneous urticaria (CSU), evaluating their stages of ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — In this video from Clinical Trials at the Summit, Carl D. Regillo, MD, FACS, discusses the use of ...

The acquisition aims to accelerate the development of targeted therapies for EGFR mutant NSCLC patients globally.

Real-world overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) systemic therapy (tx): Results from IMPACT UC II. This is an ASCO Meeting ...

Suzhou Puhe Biopharma Co. Ltd. presented promising preclinical profile data on PH009-1, a novel fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Besides ...

NASHVILLE, Tenn. -- An investigational multitargeted drug produced objective responses in clear-cell renal cell carcinoma (ccRCC), irrespective of prior exposure to cabozantinib (Cabometyx), a small ...

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 vaccinations, a new study suggests. The findings of a clinical trial led by the ...